##  [New Novartis Phase III data for brolucizumab demonstrate reliability of 12-week treatment interval](/us-en/news/media-releases/new-novartis-phase-iii-data-brolucizumab-demonstrate-reliability-12-week-treatment-interval-0 "New Novartis Phase III data for brolucizumab demonstrate reliability of 12-week treatment interval") 

  Apr 30, 2018